Suppr超能文献

维生素 D 补充对维生素 D 缺乏高发地区学龄儿童生长、身体成分和青春期发育的影响:一项随机临床试验。

Influence of Vitamin D Supplementation on Growth, Body Composition, and Pubertal Development Among School-aged Children in an Area With a High Prevalence of Vitamin D Deficiency: A Randomized Clinical Trial.

机构信息

Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

出版信息

JAMA Pediatr. 2023 Jan 1;177(1):32-41. doi: 10.1001/jamapediatrics.2022.4581.

Abstract

IMPORTANCE

Vitamin D deficiency (defined as 25-hydroxyvitamin D [25(OH)D] <20 ng/mL) is prevalent among children living in temperate climates and has been reported to associate independently with stunting, obesity, and early activation of the hypothalamic-pituitary-gonadal axis. Phase 3 randomized clinical trials to investigate the influence of long-term vitamin D replacement on growth, body composition, and pubertal development of school-aged children with vitamin D deficiency are lacking.

OBJECTIVE

To determine whether weekly oral vitamin D supplementation influences linear growth, body composition, or pubertal development in school-aged children living in a setting where vitamin D deficiency is highly prevalent.

DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a double-blind, placebo-controlled randomized clinical trial was conducted from June 2016 to June 2019 at 18 grade schools in Ulaanbaatar, Mongolia. School-aged children (6 to 13 years at baseline) attending participating schools were included. Exclusion criteria included a positive QuantiFERON-TB Gold in-tube assay result, conditions or medications associated with altered vitamin D metabolism, use of vitamin D supplements, signs of rickets, or intention to move from Ulaanbaatar within 4 years. Of 11 475 children invited to participate in the study, 9814 underwent QFT testing, and 8851 with negative results were included in the study. All but 1 participant in the placebo group completed follow-up and were included in the present analysis. Data were analyzed from November 2021 to February 2022.

INTERVENTIONS

Weekly oral doses of vitamin D3, 14 000 IU, (n = 4418), or placebo (n = 4433) for 3 years.

MAIN OUTCOMES AND MEASURES

Mean z scores for height for age, body mass index for age, and waist-to-height ratio; mean percentage body fat, fat mass, and fat-free mass; and mean Tanner scores for pubertal development.

RESULTS

Of 8851 participants, 4366 (49.3%) were female, and 8165 (92.2%) were of Khalkh ethnicity; the mean (SD) age was 9.4 (1.6) years. A total of 8453 participants (95.5%) were vitamin D deficient at baseline, and mean end-of-study 25(OH)D concentrations among participants randomized to vitamin D vs placebo were 31.0 vs 10.7 ng/mL (mean difference, 20.3; 95% CI; 19.9-20.6). However, vitamin D supplementation did not influence mean height for age, body mass index for age, waist-to-height ratio, percentage body fat, fat mass, fat-free mass, or Tanner scores, either overall or within subgroups defined by baseline 25(OH)D concentration less than 10 ng/mL vs 10 ng/mL or greater, estimated calcium intake less than 500 mg/d vs 500 mg/d or greater, or male vs female sex.

CONCLUSIONS AND RELEVANCE

In school-aged children in this study with low baseline vitamin D status, oral vitamin D3 supplementation at a dose of 14 000 IU per week for 3 years was effective in elevating 25(OH)D concentrations but did not influence growth, body composition, or pubertal development.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT02276755.

摘要

重要性

在居住在温带气候的儿童中,维生素 D 缺乏症(定义为 25-羟维生素 D [25(OH)D] <20ng/mL)很常见,并且据报道与生长迟缓、肥胖和下丘脑-垂体-性腺轴的早期激活独立相关。缺乏针对维生素 D 缺乏的学龄儿童进行长期维生素 D 替代治疗对生长、身体成分和青春期发育影响的 3 期随机临床试验。

目的

确定每周口服维生素 D 补充剂是否会影响生活在维生素 D 缺乏症高发地区的学龄儿童的线性生长、身体成分或青春期发育。

设计、地点和参与者:这是一项双盲、安慰剂对照随机临床试验的二次分析,于 2016 年 6 月至 2019 年 6 月在蒙古乌兰巴托的 18 所小学进行。参加研究的学龄儿童(基线时 6 至 13 岁)。排除标准包括 QuantiFERON-TB Gold 管内检测结果阳性、与维生素 D 代谢改变相关的病症或药物、使用维生素 D 补充剂、佝偻病迹象或计划在 4 年内离开乌兰巴托。在受邀参加研究的 11475 名儿童中,有 9814 名接受了 QFT 检测,8851 名检测结果为阴性的儿童被纳入研究。安慰剂组中除 1 名参与者外,其余均完成了随访并纳入本次分析。数据于 2021 年 11 月至 2022 年 2 月进行分析。

干预措施

每周口服维生素 D3,剂量为 14000IU(n=4418)或安慰剂(n=4433),持续 3 年。

主要观察指标

身高年龄 z 评分、体重指数年龄 z 评分和腰高比;体脂肪百分比、体脂肪量和体脂肪量;青春期发育的 Tanner 评分。

结果

在 8851 名参与者中,有 4366 名(49.3%)为女性,8165 名(92.2%)为喀尔喀人;平均(SD)年龄为 9.4(1.6)岁。共有 8453 名参与者(95.5%)在基线时维生素 D 缺乏,随机分配至维生素 D 组和安慰剂组的参与者在研究结束时 25(OH)D 浓度分别为 31.0ng/mL 和 10.7ng/mL(平均差异,20.3;95%CI;19.9-20.6)。然而,维生素 D 补充剂对身高年龄、体重指数年龄、腰高比、体脂肪百分比、体脂肪量、体脂肪量或 Tanner 评分均无影响,无论总体还是按基线 25(OH)D 浓度<10ng/mL 与≥10ng/mL、估计钙摄入量<500mg/d 与≥500mg/d 或男性与女性进行分层。

结论和相关性

在本研究中,维生素 D 基线水平较低的学龄儿童中,每周口服 14000IU 维生素 D3 3 年有效提高了 25(OH)D 浓度,但对生长、身体成分或青春期发育没有影响。

试验注册

ClinicalTrials.gov 标识符:NCT02276755。

相似文献

引用本文的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验